Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn’s disease and ulcerative colitis

被引：0
|
作者：
Diana Lacruz-Guzmán
Daniel Torres-Moreno
Francisco Pedrero
Patricia Romero-Cara
Iván García-Tercero
Javier Trujillo-Santos
Pablo Conesa-Zamora
机构：
[1] Santa Lucía General University Hospital (HGUSL),Pharmacy Department
[2] HGUSL,Molecular Pathology and Pharmacogenetics Group FFIS011, Pathology Department
[3] HGUSL,Day Hospital
[4] HUGSL,Gastroenterology Department
[5] HUGSL,Internal Medicine
来源：
European Journal of Clinical Pharmacology | 2013年 / 69卷
关键词：
Tumour necrosis factor; Interleukin-1; Infliximab; Crohn’s disease; Pharmacogenetics; Ulcerative colitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：431 / 438
页数：7
相关论文
共 50 条
  • [41] Serologic response to Streptococcus mutans in Crohn's disease and ulcerative colitis.
    Holland, S
    GASTROENTEROLOGY, 1998, 114 (04) : A997 - A997
  • [42] Duration of Crohn's disease does not influence patient's response to infliximab
    Weinberg, AM
    Lewis, JD
    Su, CG
    Lichtenstein, GR
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S254 - S254
  • [43] Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis
    Hanzel, Jurij
    Bukkems, Laura H.
    Gecse, Krisztina B.
    D'Haens, Geert R.
    Mathot, Ron A. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) : 1309 - 1319
  • [44] Is there a difference in trough levels and immunogenicity between Crohn's disease and ulcerative colitis patients treated with infliximab?
    Perdigoto, D.
    Macedo, C.
    Portela, F.
    Lopes, S.
    Ferreira, M.
    Ferreira, M.
    Mendes, S.
    Tome, L.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S475 - S475
  • [45] A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis
    Peyrin-Biroulet, L.
    Arkkila, P.
    Armuzzi, A.
    Atreya, R.
    Danese, S.
    Ferrante, M.
    Guardiola, J.
    Jahnsen, J.
    Louis, E.
    Lukas, M.
    Reinisch, W.
    Roblin, X.
    Smith, P. J.
    Kwon, T. S.
    Kim, J. Y.
    Yoon, S. W.
    Kim, D. H.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I1116 - I117
  • [46] PROSPECTIVE STUDY OF PHARMACOKINETICS OF INFLIXIMAB DURING INDUCTION IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS (PACIFIC)
    Liefferinckx, Claire
    Bossuyt, Peter
    Thomas, Debby
    Rahier, Jean-Francois
    Louis, Edouard
    Baert, Filip J.
    Dewint, Pieter
    Pouillon, Lieven
    Lambrecht, Guy
    Vermeire, Severine
    Franchimont, Denis
    GASTROENTEROLOGY, 2020, 158 (06) : S456 - S456
  • [47] COST-MINIMIZATION ANALYSIS OF INFLIXIMAB VERSUS ADALIMUMAB IN THE TREATMENT OF CROHN'S DISEASE AND ULCERATIVE COLITIS
    De Paula, E.
    Blumer, V. D.
    Trevizam, Y. C.
    Asano, E. W.
    VALUE IN HEALTH, 2015, 18 (03) : A296 - A296
  • [48] Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn's disease and ulcerative colitis (PACIFIC)
    Liefferinckx, C.
    Bossuyt, P.
    Thomas, D.
    Rahier, J. F.
    Louis, E.
    Baert, F.
    Dewint, P.
    Pouillon, L.
    Lambrecht, G.
    Vermeire, S.
    Franchimont, D.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S343 - S344
  • [49] Association of TNF and Fc gamma RIIIA gene polymorphisms with differential response to infliximab in a Greek cohort of Crohn's disease patients
    Papamichael, Konstantinos
    Gazouli, Maria
    Karakoidas, Christos
    Panayotou, Ioanna
    Roma-Giannikou, Eleftheria
    Mantzaris, Gerassimos J.
    ANNALS OF GASTROENTEROLOGY, 2011, 24 (01): : 35 - 40
  • [50] Identifying Anti-TNF Use for Crohn's Disease and Ulcerative Colitis in Primary Care
    Maguire, Andrew
    Puelles, Jorge
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 518 - 519
12345